Patents Issued in April 11, 2017
-
Patent number: 9616014Abstract: Cosmetic agents, in some embodiments in powder form, containing as component (a) at least one polymer comprising at least one structural unit of formula (I) and at least one structural unit of formula (II), in which X denotes a physiologically acceptable cation (in particular Na+), R1 denotes a hydrogen atom or a methyl group and R2 denotes a (C2 to C6) hydroxyalkyl group, and as component (b) at least one setting polymer, are suitable for temporarily reshaping keratin-containing fibers. When applied to human hair, for example, an elastic hairstyle with volume was obtained. The hair retained its natural gloss.Type: GrantFiled: November 9, 2012Date of Patent: April 11, 2017Assignee: HENKEL AG & CO. KGAAInventors: Thorsten Knappe, Anna Henschel, Julia Bibane Lange
-
Patent number: 9616015Abstract: Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof.Type: GrantFiled: June 11, 2015Date of Patent: April 11, 2017Assignee: DiaMedica Inc.Inventor: Matthew Charles
-
Patent number: 9616016Abstract: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.Type: GrantFiled: November 19, 2010Date of Patent: April 11, 2017Assignee: SANTEN SASInventors: Frédéric Lallemand, Jean-Sébastien Garrigue, Jeffrey Heier
-
Patent number: 9616017Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.Type: GrantFiled: April 22, 2016Date of Patent: April 11, 2017Assignee: Allergan, Inc.Inventors: Anuradha V. Gore, Sai Shankar, Sukhon Likitlersuang, Chetan P. Pujara, Sesha Neervannan
-
Patent number: 9616018Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.Type: GrantFiled: February 17, 2016Date of Patent: April 11, 2017Assignee: Aprecia Pharmaceuticals CompanyInventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
-
Patent number: 9616019Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.Type: GrantFiled: April 1, 2015Date of Patent: April 11, 2017Assignee: Celgene CorporationInventors: Ming J. Chen, Ho-Wah Hui, Thomas Lee, Paul Kurtulik, Sekhar Surapaneni
-
Patent number: 9616020Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.Type: GrantFiled: April 13, 2016Date of Patent: April 11, 2017Assignee: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Jaehyun Moon
-
Patent number: 9616021Abstract: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses.Type: GrantFiled: March 10, 2014Date of Patent: April 11, 2017Inventors: Omathanu P Perumal, Satheesh K Podaralla, Radhey S Kaushik
-
Patent number: 9616022Abstract: The subject invention provides materials and methods for treating diseases affecting the central nervous system (CNS) and/or other viral reservoir organs utilizing nanoscopic diamond particles, i.e., nanodiamonds (ND), loaded with therapeutic agents of interests. In one aspect, the subject invention provides a composition for treating a subject's brain and/or other organs acting as viral reservoirs, the composition comprising a plurality of ND particles measuring less than 10 nm in size, wherein the ND particles are loaded with at least one therapeutic agent of interest. In another aspect, the subject invention provides methods of treating disorders affecting the CNS such as, for example, the brain and other viral reservoir organs such as, for example, lymph nodes and gut-associated lymphoid tissues (GALT), utilizing the drug delivery system comprising a plurality of ND particles as provided herein.Type: GrantFiled: July 7, 2016Date of Patent: April 11, 2017Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Upal Roy, Vadym Drozd, Madhavan Nair, Surendra K. Saxena, Andriy Durygin
-
Patent number: 9616023Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.Type: GrantFiled: July 6, 2015Date of Patent: April 11, 2017Assignee: G. Pohl-Boskamp GmbH & Co. KGInventors: Thomas Zimmeck, Henning Ueck, Julia Gehricke
-
Patent number: 9616024Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.Type: GrantFiled: April 25, 2016Date of Patent: April 11, 2017Assignee: Norton Healthcare Ltd.Inventors: Xian-Ming Zeng, Seah Kee Tee
-
Patent number: 9616025Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid ?9-tetrahydrocannabinol(THC). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment •30-90 wt % of a granulate; •10-70 wt % of lactose; and •0-30 wt % of other tablet excipients; wherein the granulate contains: a.2-5 wt % of ?9-tetrahydrocannabinol; b.2-20 wt % of sucrose fatty acid mono-ester; c.50-96 wt % of lactose; d.0.05-0.6 wt % of antioxidant; and e.0-25 wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer's disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea.Type: GrantFiled: October 29, 2014Date of Patent: April 11, 2017Assignee: Echo Pharmaceuticals B.V.Inventors: Jan Albert De Vries, Maria Vanesa Fernandez Cid, Ana Maria Heredia Lopez, Cristina Maria Eiroa Martinez
-
Patent number: 9616026Abstract: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.Type: GrantFiled: September 5, 2008Date of Patent: April 11, 2017Assignee: The Roshni Singh 2015 TrustInventor: Bramah N. Singh
-
Patent number: 9616027Abstract: The present invention relates to a method for preparing the sustained-release tablets via direct compression process, wet granulation process or dry granulation process to obtain the formulations. The present invention also provides a use of the sustained-release tablet formulation of pramipexole in the preparation of pharmaceutical compositions. A sustained release tablet formulation has advantages as follows: breaking out patent monopoly of the innovator preparation, drug dissolution release effects in vitro can be achieved and probably clinical treatment effects can also be accomplished consistent with that of the innovator preparation; abandoning anionic polymers used in the innovator preparation such that making the drug release and absorption not being influenced by the patent body's gastric pH values, in order to avoid the disadvantages of the innovator preparation.Type: GrantFiled: October 9, 2014Date of Patent: April 11, 2017Assignee: SHIJIAZHUANG RAPISTEP PHARMACEUTICAL TECHNOLOGY R&D INC.Inventors: Qing Ren, Chaoyun Hu, Jingya Song, Xizheng Ma
-
Patent number: 9616028Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: May 7, 2015Date of Patent: April 11, 2017Assignees: AstraZeneca AB, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9616029Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.Type: GrantFiled: March 25, 2015Date of Patent: April 11, 2017Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Dilip Shanghvi
-
Patent number: 9616030Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: GrantFiled: March 14, 2014Date of Patent: April 11, 2017Assignee: Purdue Pharma L.P.Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Patent number: 9616031Abstract: The present invention relates to a method for encapsulating particles of a water-insoluble material within a capsule of a water-insoluble polymer, comprising (a) dispersing particles of the water-insoluble material or a solution containing the water-insoluble material in a first aqueous phase containing a first surfactant to obtain a first dispersion; (b) collecting the particles of the water-insoluble material coated with the first surfactant; (c) washing the collected particles; (d) adding the washed surfactant-coated water-insoluble material particles to a polymer solution containing the water-insoluble polymer of the capsule to obtain a polymer mixture; and (e) dispersing the polymer mixture in a second aqueous phase containing a second surfactant to obtain a second dispersion comprising the particles of the water-insoluble material encapsulated within the capsule of the water-insoluble polymer.Type: GrantFiled: November 24, 2011Date of Patent: April 11, 2017Assignee: Nanyang Technological UniversityInventors: Say Chye Joachim Loo, Yit Lung Khung, Wei Li Lee
-
Patent number: 9616032Abstract: There are provided compositions for extended release of a nucleic acid agent, comprising a lipid-saturated matrix formed with a biodegradable polymer. Also provided are methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.Type: GrantFiled: August 4, 2014Date of Patent: April 11, 2017Assignee: Polypid Ltd.Inventors: Noam Emanuel, Yosef Rosenfeld
-
Patent number: 9616033Abstract: Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and uridine diphosphate glucoronysl transferases, aka UGTs. Preferably the inhibitors are GRAS compounds. The one or more inhibitor compounds inhibit the enzymes responsible for rapid presystemic metabolism, thus allowing the bioactives (e.g., phenylephrine) to be more readily absorbed intact into the circulatory system.Type: GrantFiled: September 27, 2012Date of Patent: April 11, 2017Assignee: Virginia Commonwealth UniversityInventors: Phillip M. Gerk, William H. Barr, Joseph K. Ritter
-
Patent number: 9616034Abstract: The present invention relates to the administration of compositions comprising trans-clomiphene or an analog or salt thereof, for inhibiting bone resorption and bone turnover in a subject. The invention is also directed to methods for increasing bone mineral density in a subject and preventing or treating a bone related disorder in a subject comprising administering to the subject an effective amount of trans-clomiphene or an analog or salt thereof.Type: GrantFiled: June 3, 2014Date of Patent: April 11, 2017Assignee: REPROS THERAPEUTICS INC.Inventors: Joseph S. Podolski, Kuang Hsu, Ronald D. Wiehle, Greg Fontenot, Jaye Thompson
-
Patent number: 9616035Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: GrantFiled: October 25, 2013Date of Patent: April 11, 2017Assignee: PATHOLOGICA, LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 9616036Abstract: A sustained release dosage form comprises an active ingredient blended with a polymeric matrix. At least a portion of the polymeric matrix is formed by a cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that [s23/s26?0.2*MS(hydroxyalkyl)] is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group.Type: GrantFiled: April 8, 2013Date of Patent: April 11, 2017Inventors: Meinolf Brackhagen, Roland Adden, Oliver Petermann, Robert L. Sammler, David E. Wallick
-
Patent number: 9616037Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).Type: GrantFiled: March 21, 2016Date of Patent: April 11, 2017Assignee: PIMCO 2664 LimitedInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van't Hof
-
Patent number: 9616038Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.Type: GrantFiled: July 22, 2015Date of Patent: April 11, 2017Assignee: Neurocentria, Inc.Inventors: Guosong Liu, Fei Mao
-
Patent number: 9616039Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.Type: GrantFiled: June 2, 2016Date of Patent: April 11, 2017Assignee: CYMABAY THERAPEUTICS, INC.Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
-
Patent number: 9616040Abstract: Spinal stenosis is a common debilitating illness that produces symptoms of neurogenic claudication, radiculopathy and weakness. Present therapies include administration of analgesics, epidural injections of local anesthetic with corticosteroids and decompression laminectomy. In vitro, citrate ion can resorb vertebral cortical bone by chelating calcium without destruction of the ligamentum flavum or dura mater. This non-enzymatic spontaneous chemical reaction occurs at neutral pH, 37° C. and in an isotonic solution and in vitro produces an average cortical bone weight loss of 17% after 168 hours. In this invention epidural infusion of citrate in the form of an isotonic solution of sodium citrate/citric acid buffer at neutral pH will resorb a significant amount of vertebral bone such that the symptoms of spinal stenosis are ameliorated.Type: GrantFiled: January 9, 2016Date of Patent: April 11, 2017Inventor: Joel Steven Goldberg
-
Patent number: 9616041Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.Type: GrantFiled: December 14, 2012Date of Patent: April 11, 2017Assignee: Emmaus Medical, Inc.Inventor: Yutaka Niihara
-
Patent number: 9616042Abstract: A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is 2H and/or at least one C atom is 13C. The nutrient is thus protected from, inter alia, active oxygen species.Type: GrantFiled: March 23, 2016Date of Patent: April 11, 2017Assignee: Retrotope, Inc.Inventor: Mikhail Sergeevich Shchepinov
-
Patent number: 9616043Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: September 11, 2015Date of Patent: April 11, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9616044Abstract: The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterized in that the composition includes a non-aqueous carrier and a solvent system comprising castor oil and at least one cyclic amide.Type: GrantFiled: March 13, 2013Date of Patent: April 11, 2017Inventors: Fadil Al Alawi, Karthigeyan Nanjan
-
Patent number: 9616045Abstract: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.Type: GrantFiled: October 3, 2014Date of Patent: April 11, 2017Assignee: LTS Lohmann Therapie-Systeme AGInventors: Thomas Hille, Lothar Deurer
-
Patent number: 9616046Abstract: The present invention relates to a hepatocyte-proliferating agent comprising pyroglutamic acid, aspartic acid, and glutamic acid as active ingredients, in particular, a hepatocyte-proliferating agent capable of selectively proliferating normal hepatocytes without proliferating cancer cells.Type: GrantFiled: June 16, 2014Date of Patent: April 11, 2017Assignee: JAPAN BIO PRODUCTS Co., Ltd.Inventors: Shinjiro Inoue, Eiichi Hirano, Tetsuo Morinaga
-
Patent number: 9616047Abstract: Compounds are disclosed which are effective for inhibiting ?-catenin or disrupting a ?-catenin/Tcf-4 complex, and for causing effective attenuation of colon carcinogenesis. The compounds may be effective treatment for colorectal cancer (CRC) when administered in an effective dose to a patient afflicted therewith.Type: GrantFiled: June 30, 2015Date of Patent: April 11, 2017Assignee: Regents of University of MinnesotaInventors: Ann Marie Bode, Zigang Dong, Srinivasa Reddy Kanamata Reddy
-
Patent number: 9616048Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: GrantFiled: October 19, 2015Date of Patent: April 11, 2017Assignee: Board of Regents of The University of Texas SystemInventors: Steven L. McKnight, Andew A. Pieper, Joseph M. Ready, Jef K. De Brabander, Jeffrey M. Zigman
-
Patent number: 9616049Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: March 2, 2016Date of Patent: April 11, 2017Assignee: HOSPIRA, INC.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Patent number: 9616050Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: August 31, 2015Date of Patent: April 11, 2017Assignee: AstraZeneca ABInventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
-
Patent number: 9616051Abstract: Topoisomerase II alpha (topo II?) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo II? is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo II? to the export receptor CRM1. Inhibition was specific to topo II? as p53 trafficking was unaffected along with topo II? protein expression and function (decatenation). These topo II?-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.Type: GrantFiled: June 3, 2013Date of Patent: April 11, 2017Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of Florida Research Foundation, Inc.Inventors: Daniel M. Sullivan, Thomas C. Rowe, David A. Ostrov, Joel G. Turner
-
Patent number: 9616052Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.Type: GrantFiled: November 8, 2016Date of Patent: April 11, 2017Inventor: Thomas P. Dooley
-
Patent number: 9616053Abstract: The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar, X, X1, R1, R2, R3, m, n and the dotted line are as defined herein which compounds are useful for treating certain central nervous system disorders as described herein.Type: GrantFiled: December 16, 2015Date of Patent: April 11, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Daniela Brunner, Hans Hilpert, Sabine Kolczewski, Anja Limberg, Jessica Malberg, Eric Prinssen, Claus Riemer, Bavani G. Shankar, Theodor Stoll
-
Patent number: 9616054Abstract: The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting local anesthetic combined with clonidine. The combination of the two pharmaceuticals produces a significant increase in duration and speed of onset of sympathetic blockade, increased intensity of the sympathetic blockage as well as the reduction of local anesthetic absorption locally. The combination significantly improves the efficacy, speed of onset and block intensity of a right sided cervical sympathetic ganglion injection (RCSGI) leading to increased length of resolution of PTSD and hot flashes as well as reducing the potential for complications related to absorption of the local anesthetic.Type: GrantFiled: March 17, 2015Date of Patent: April 11, 2017Assignee: CAD Medical Solutions, LLCInventor: Eugene Lipov
-
Patent number: 9616055Abstract: Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.Type: GrantFiled: July 2, 2015Date of Patent: April 11, 2017Assignee: Durect CorporationInventors: Jan J. Scicinski, William W. van Osdol, Huey-Ching Su, Michael H. Arenberg, Jaymin Shah
-
Patent number: 9616056Abstract: Treating Sonic Hedgehog-Associated Medulloblastoma comprises inhibiting the synthesis or biologic activity of leukotrienes that drive Nestin expression in cancerous or precancerous granule neuron precursors and that further drive growth and proliferation of medulloblastoma cells through Nestin-mediated aberrant Sonic Hedgehog signaling.Type: GrantFiled: March 15, 2013Date of Patent: April 11, 2017Assignee: Institute for Cancer ResearchInventor: Zeng-Jie Yang
-
Patent number: 9616057Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.Type: GrantFiled: March 14, 2014Date of Patent: April 11, 2017Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans AffairsInventors: William H. Robinson, Jeremy Sokolove, Qian Wang
-
Patent number: 9616058Abstract: The present invention relates to the use of potent selective LSD inhibitors and LSD/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency.Type: GrantFiled: February 24, 2011Date of Patent: April 11, 2017Assignee: Oryzon Genomics, S.A.Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Muñoz, Nathalie Guibourt, Jonathan Alleman Baker
-
Patent number: 9616059Abstract: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.Type: GrantFiled: December 16, 2015Date of Patent: April 11, 2017Assignee: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Andrea Lombardi Borgia, Maria Menichincheri, Paolo Orsini, Achille Panzeri, Ettore Perrone, Ermes Vanotti, Marcella Nesi, Chiara Marchionni
-
Patent number: 9616060Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.Type: GrantFiled: August 4, 2014Date of Patent: April 11, 2017Assignee: Nektar TherapeuticsInventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
-
Patent number: 9616061Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: GrantFiled: October 16, 2015Date of Patent: April 11, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
-
Patent number: 9616062Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.Type: GrantFiled: December 11, 2013Date of Patent: April 11, 2017Assignee: The University of North Carolina at Chapel HillInventors: Norman E. Sharpless, Patrick J. Roberts, Kwok-Kin Wong, Soren Johnson
-
Patent number: 9616063Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.Type: GrantFiled: November 25, 2015Date of Patent: April 11, 2017Assignee: AstraZeneca ABInventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse